PhaseBio Pharmaceuticals, a clinical-stage biopharmaceutical company developing therapies for the treatment of orphan diseases, has been awarded a $2.8 million grant.

The Fast Track Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) will be used to support the clinical development of PB1046 – a first-in-class, sustained-release vasoactive intestinal peptide analogue – in patients with pulmonary arterial hypertension (PAH).

[uam_ad id=”58459″]

Advertisement

“Recent advancements in the treatment of PAH have improved patient symptoms and exercise capacity but are not curative, and long-term disease prognosis remains poor, leaving the door open for innovative new therapeutic options like PB1046,” said John Lee, PhaseBio’s Chief Medical Officer.

“This grant award validates our therapeutic approach and PhaseBio’s position as an emerging player in the development of innovative therapies for rare diseases,” said Jonathan P. Mow, PhaseBio’s CEO.

[uam_ad id=”71915″]